30.04.2015
Medibiome AB preliminary report
Medibiome AB issues today a preliminary report of first results of Vernex™ exposure to human skin explants showing improved and faster reepitelialization of seconday degree induced burn wounds over placebo.
17.04.2015
In-cosmetics Barcelona 2015
Regenics visited in-cosmetics in Spain, which held on 14-16th April. Participation in the largest cosmetics fairs in Europe was for Regenics great opportunity to meet with current customers and establish...
16.04.2015
BIA 2015 grant to Regenics AS
Regenics receieves 2015-2018 R&D grant from Norwegian Research Council in the BIA (brukerstyrt innovasjonsarena) programme.
02.04.2015
Regenics AS Annual Report 2014
Regenics AS Annual Report 2014
11.03.2015
2015 Eurostars funding to Regenics
Regenics is awarded Eurostars R&D funding for Vernex® wound healing device development.
25.02.2015
Medibiome AB collaboration
Medibiome AB, Sweden and Regenics AS Oslo agrees collaboration on evaluation of Vernex™ in human skin explant model.
08.02.2015
Orkla-Lilleborg launches AquaDerma
Lilleborg launches AquaDerma - a new, LEX® containing cosmetic series in Norway.
13.01.2015
LEX® trademark issued in US
The trademark LEX® for salmon roe extract used for cosmetic purposes has today been approved by US Patent Office 
01.01.2015
Dominika Andrys joins Regenics
Dominika Andrys joins Regenics
17.06.2014
Regenics AS Annual Report 2013
Regenics AS Annual Report 2013
06.04.2014
In-cosmetics Hamburg 2014
On 1-3th April 2014, Regenics, along with other exhibitors of beauty industry gathered in the in-cosmetics in Germany. Regenics with great success presented itself at the largest cosmetic industry exhibition...
13.03.2014
Regenics appoints new head of production
We are welcome new Production Manager Markus Heldrup. Heldrup will be handling technical production of our bioactive ingredient Salmon Roe Extract and he will be also supporting technical R&D. Markus Heldrup is BSc...
01.03.2014
Hege Ugland leaves Regenics
Hege Ugland leaves Regenics
01.03.2014
Regenics attends In-cosmetics Hamburg 1-3 April 2014
Chief Scientific Officer Gry Lønne will present marine ingredients in cosmetics and health indications Tue April 1 at 3.10 pm in Theatre 3. Please visit us at stand 1G01.    
29.01.2014
Christian Clemm CMO
Christian Clemm, MD, MBA is apointed Chief Medical Officer for Regenics AS.
08.10.2013
Henrik Lund CEO
Henrik Lund MD, PhD appointed CEO of Regenics AS

<<  <   Page 4 of 5   >  >>

REGENICS AT EVENTS

June 5-6th 2017

Investor Conference Biotech-Medtech, at Stavanger Forum Oslo

Program (tbd)

March 9th 2017

Roundtable Conference in investing in Biotech, CEO Henrik Lund, moderator for the Event at Stavanger Forum Oslo

Program Roundtable Conference Stavanger

March 8th 2017

War on Cancer Nordics, CEO Henrik Lund participating in closing panel at the Economist Event in Oslo

Program Economist Event Oslo

December 15th 2016

DnB Healtcare Conference 2016, CMO Christian Clemm provides company update in the ventture session

Regenics presentation   

October 19-20-21 2016

Biomarine Convention, CEO Henrik Lund, participating at Convention in Oslo

Program Biomarine Business Conference

October 19th 2016

DnB Next at Oslo Innovation Week, CSO Gry Lønne, presenting Regenics Company update in Oslo

program DNB Next healthcare      Regenics presentation 

September 25-28 2016

At the 4th Congress on Innovation in Drug Delivery in Antibes, Regenics publish data on its carrier/vehicle GMO to be used in the CE marking device for wound healing.

Abstract 4th Congress on Innovation in Drug Delivery

October 22-24 2015

At the Joint Meeting of the European Tissue Repair Society (ETRS) and the Wound Healing Society (WHS), Regenics showed excellent and rapid wound healing of its wound healing device Vernex under development for CE-marking in 2018. In 2nd degree burn wounds Vernex provided rapid and complete reepitelialization of epidemal keratinocytes in human explanted skin. This represent a prooof of priciple for the utility of Vernex in human wound healing. 

Abstract 7th ETRS-WHS meeting

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.